US 10646443
Sustained release olanzapine formulations
granted A61KA61K31/551A61K31/5513
Quick answer
US patent 10646443 (Sustained release olanzapine formulations) held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICALS INTERNATIONAL GMBH
- Grant date
- Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 58
- CPC classes
- A61K, A61K31/551, A61K31/5513, A61K47/34, A61K9/0019